BioIntel is now The Catalyst Brief.
The Catalyst Brief
Coverage

Regulatory & Policy

FDA actions, approvals, policy shifts and compliance: how the rules change timelines and probability.

Page 41 of 43

Archive

Spending Bill Clears House, Keeping Priority Review Voucher Hopes AliveJan 23, 2026

Spending Bill Clears House, Keeping Priority Review Voucher Hopes Alive

The rare pediatric disease priority review voucher program, a key FDA initiative designed to incentivize drug development for rare pediatric diseases, faced uncertainty after missing reauthorization in 2024. The recent House spending bill vote signals potential for revival as the bill moves to the Senate.

The Catalyst Brief
Lawmakers Grill Health Insurance CEOs: 4 Key TakeawaysJan 23, 2026

Lawmakers Grill Health Insurance CEOs: 4 Key Takeaways

Amid rising healthcare expenses and growing scrutiny, lawmakers conducted two House hearings to interrogate health insurance CEOs. The discussions revealed key insights into the industry's stance on cost drivers, structural market dynamics, and administrative hurdles that affect patient care and system efficiency.

The Catalyst Brief
Slingshot AI Withdraws Therapy Chatbot Ash from UK Market Over Regulatory HurdlesJan 21, 2026

Slingshot AI Withdraws Therapy Chatbot Ash from UK Market Over Regulatory Hurdles

The removal of Ash, a therapy chatbot developed by Slingshot AI, from the UK market highlights the increasing scrutiny and regulatory challenges faced by digital therapeutic tools. This article analyzes the regulatory environment, the implications for digital mental health products, and the broader context of AI-driven therapies.

The Catalyst Brief
Congress Revives Bipartisan Health Care Proposal Including Drug Middlemen ProvisionsJan 20, 2026

Congress Revives Bipartisan Health Care Proposal Including Drug Middlemen Provisions

After previously being stymied, elements of a bipartisan health care package have reemerged in Congressional discussions. Central to the proposal are updated regulations on pharmacy benefit managers and strategies to mitigate drug pricing inflation, reflecting the complexity and urgency in reforming the U.S. health care system.

The Catalyst Brief
Kaiser Permanente to Pay $556M to Settle Medicare Advantage Fraud AllegationsJan 16, 2026

Kaiser Permanente to Pay $556M to Settle Medicare Advantage Fraud Allegations

The settlement marks one of the largest risk-adjustment settlements in recent history, underscoring ongoing federal scrutiny of Medicare Advantage programs. This case highlights the complexities and regulatory challenges facing healthcare organizations operating within government programs.

The Catalyst Brief
Jazz Sells Priority Review Voucher for $200M as Program’s Renewal Stalls in SenateJan 15, 2026

Jazz Sells Priority Review Voucher for $200M as Program’s Renewal Stalls in Senate

Jazz Pharmaceuticals recently sold one of its Priority Review Vouchers (PRVs) for $200 million, marking a substantial financial transaction as the future of the PRV program hangs in the balance due to legislative delays. The details of the buyer remain undisclosed, and the allocation of the remaining proceeds is unclear, emphasizing the nuanced complexities in biotech regulatory incentives.

The Catalyst Brief

Other beats

AI in Drug Discovery

Machine learning, predictive models and computational biology: how AI is changing discovery workflows and probability of success.

Biopharmaceutical Industry

Drug development, clinical trials and industry dynamics. What changes timelines, risk and competitive positioning.

Biotech Innovation

Gene therapy, CRISPR, synthetic biology and emerging platforms. Separating what is real from what is hype, and what actually translates.

Healthcare Investment

Where capital is flowing and why the tape moves, across funding rounds, M&A, IPOs and market analysis.

Medical Technology

Digital health, diagnostics and medical devices, and the signals that matter for adoption, reimbursement and outcomes.